Cancer's New Kryptonite: Nanoparticles Tackle Tumors Without Side Effects

In a new study, immunostimulatory drugs slowed tumor growth without producing systemic inflammation. MIT researchers discovered that immunostimulatory prodrugs with optimized activation timing can slow tumor growth without causing systemic inflammation. This approach could enhance immune responses in cancer patients when combined with other treatments.